Requip for Healthcare Providers: Clinical Data

Requip: Consumer Home | Restlesslegs.com | Prescribing Information

Home

Etiology of RLS

Treatment With Requip

Mechanism of Action Dosing and Titration Efficacy Tolerability

Clinical Data

Tools and Materials

Requip for Parkinson's
Disease

Clinical Data

Treatment With Requip Achieved Statistically Significant Results

*TREAT=Therapy with Ropinirole, Efficacy and Tolerability.

†RESET PLM=Ropinirole Efficacy and Safety in the Treatment of Periodic Leg Movements

Improvement in RLS Symptom Severity After 2 Nights and Continued Through Week 12

Requip is indicated for patients with moderate-to-severe primary RLS.

Requip has been associated with sedating effects, including somnolence, and the possibility of falling asleep while engaged in activities of daily living, including operation of a motor vehicle. Syncope or symptomatic hypotension may occur, particularly during initial treatment or dose titration. Impulse control symptoms, including pathological gambling and hypersexuality, have been reported in patients treated with dopaminergic agents, including ropinirole.

For More Safety Information about Requip, click here.

Complete Prescribing Information for Requip® (ropinirole HCl) Tablets